MetaCap

LeonaBio (LONA) vs Genenta Science S.p.A. (SAEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

LeonaBio is the larger company by market cap ($26.4 million vs $24.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LONA-57.65%SAEN-47.19%
+3%-29%-61%
Nov 3, 20261 yearNov 20, 2026
LONA-54.25%SAEN-23.70%
+3%-27%-57%
Nov 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LONA versus SAEN key metrics
MetricLONASAEN
Share price$2.02$0.5074
Market cap$26.41M$24.47M
1-day change-17.89%-9.39%
YTD return-73.32%—
1-year return-56.13%—
5-year return-98.55%—
EPS (TTM)$-22.20$-0.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-105.61M—
52-week high$14.21$2.58
52-week low$1.91$0.50
Distance from 52-week high-85.78%-80.33%
Analyst consensusnone—
Avg. price target upside+757.92%—
Average volume195.37K85.01K
Shares outstanding13.08M48.22M
Employees199
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About LeonaBio

LONA stock →

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees

About Genenta Science S.p.A.

SAEN stock →

Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 9 employees

LONA vs SAEN FAQ

Which is bigger, LeonaBio or Genenta Science S.p.A.?

LeonaBio (LONA) is larger, with a market capitalization of $26.41M compared with $24.47M for Genenta Science S.p.A. (SAEN).

Are LeonaBio and Genenta Science S.p.A. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons